Seattle Genetics' "next opportunity for a commercial product" – following on from the success of its Takeda-partnered Hodgkin's lymphoma drug Adcetris (brentuximab vedotin) – will move into Phase III trials in 2016.
President and CEO of Seattle Genetics Dr. Clay Siegall told Scrip in a recent interview that while "Adcetris is spectacular...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?